Antipsychotics decrease response confidence

Standard

Antipsychotics decrease response confidence. / Moritz, Steffen; Kolbeck, Katharina; Andreou, Christina.

in: J PSYCHOPHARMACOL, Jahrgang 30, Nr. 8, 08.2016, S. 831-3.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{a260752ebb724deda73279ee5d43a090,
title = "Antipsychotics decrease response confidence",
abstract = "Antipsychotics represent the first-choice treatment for schizophrenia. However, the cognitive and emotional pathways through which symptom reduction is achieved have remained unclear. We recently proposed that the induction of doubt is a core mechanism of action of antipsychotics. In the framework of a randomized, double-blind, placebo-controlled, crossover design, 39 nonclinical participants filled out a questionnaire tapping into cognitive and emotional changes (Effect of Antipsychotic Medication on Emotion and Cognition-revised (EAMEC-r)) each time they had received one of three substances (haloperidol, placebo, L-dopa). Participants reported more doubt under haloperidol than under L-dopa lending support to the theory that antipsychotics decrease delusional conviction via the reduction of confidence. Key points from this study are: (a) antipsychotics induce doubt, and (b) doubt may represent a core mechanism of action for the reduction of delusional ideas.",
author = "Steffen Moritz and Katharina Kolbeck and Christina Andreou",
note = "{\textcopyright} The Author(s) 2016.",
year = "2016",
month = aug,
doi = "10.1177/0269881116650404",
language = "English",
volume = "30",
pages = "831--3",
journal = "J PSYCHOPHARMACOL",
issn = "0269-8811",
publisher = "SAGE Publications",
number = "8",

}

RIS

TY - JOUR

T1 - Antipsychotics decrease response confidence

AU - Moritz, Steffen

AU - Kolbeck, Katharina

AU - Andreou, Christina

N1 - © The Author(s) 2016.

PY - 2016/8

Y1 - 2016/8

N2 - Antipsychotics represent the first-choice treatment for schizophrenia. However, the cognitive and emotional pathways through which symptom reduction is achieved have remained unclear. We recently proposed that the induction of doubt is a core mechanism of action of antipsychotics. In the framework of a randomized, double-blind, placebo-controlled, crossover design, 39 nonclinical participants filled out a questionnaire tapping into cognitive and emotional changes (Effect of Antipsychotic Medication on Emotion and Cognition-revised (EAMEC-r)) each time they had received one of three substances (haloperidol, placebo, L-dopa). Participants reported more doubt under haloperidol than under L-dopa lending support to the theory that antipsychotics decrease delusional conviction via the reduction of confidence. Key points from this study are: (a) antipsychotics induce doubt, and (b) doubt may represent a core mechanism of action for the reduction of delusional ideas.

AB - Antipsychotics represent the first-choice treatment for schizophrenia. However, the cognitive and emotional pathways through which symptom reduction is achieved have remained unclear. We recently proposed that the induction of doubt is a core mechanism of action of antipsychotics. In the framework of a randomized, double-blind, placebo-controlled, crossover design, 39 nonclinical participants filled out a questionnaire tapping into cognitive and emotional changes (Effect of Antipsychotic Medication on Emotion and Cognition-revised (EAMEC-r)) each time they had received one of three substances (haloperidol, placebo, L-dopa). Participants reported more doubt under haloperidol than under L-dopa lending support to the theory that antipsychotics decrease delusional conviction via the reduction of confidence. Key points from this study are: (a) antipsychotics induce doubt, and (b) doubt may represent a core mechanism of action for the reduction of delusional ideas.

U2 - 10.1177/0269881116650404

DO - 10.1177/0269881116650404

M3 - SCORING: Journal article

C2 - 27222269

VL - 30

SP - 831

EP - 833

JO - J PSYCHOPHARMACOL

JF - J PSYCHOPHARMACOL

SN - 0269-8811

IS - 8

ER -